Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies

Fredman, Danielle, McNeil, Rotem, Eldar, Ofir, Leader, Avi, Gafter-Gvili, Anat, Avni, Tomer · 2023 · Journal of Thrombosis and Thrombolysis

Abstract

Background Direct-acting oral anticoagulants (DOACs) including rivaroxaban and apixaban are preferred over vitamin K antagonists for the treatment of venous thromboembolism (VTE). We conducted a systematic review and a meta-analysis to compare the efficacy and safety of rivaroxaban versus apixaban in the treatment of VTE. Methods We conducted an electronic search for studies that directly compared treatment with rivaroxaban and apixaban in adult patients with VTE. The relative risks (RRs) and 95% confidence intervals (CIs) were estimated and pooled using a fixed-effect model unless significant heterogeneity was present (I 2 > 40%), then random-effects model was used. The primary efficacy and safety outcomes were recurrent VTE (rVTE) and major bleeding events, respectively. Results Nine observational studies were included in our meta-analysis, assessing 24,156 patients for apixaban and 38,847 for rivaroxaban. Pooling of data for our primary efficacy outcome showed a trend towards lower risk of rVTE with apixaban compared to rivaroxaban (RR 0.77, 95% CI 0.57-1.04, I 2 = 53%). Analysis of our primary safety outcome showed a significantly lower risk of major bleeding with apixaban compared to rivaroxaban (RR 0.68, 95% CI 0.61-0.76, I 2 = 0%). Apixaban was associated with significantly decreased risk of net clinical harm, clinically relevant non major bleeding (CRNMB) and any bleeding, compared to rivaroxaban (RR 0.75, 95% CI 0.61-0.92, I 2 = 50%; RR 0.58, 95% CI 0.50-0.67, I 2 =…

Overview

Integrity signals

Registry

Crossref · 10.1007/s11239-023-02926-3

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Higgins JPT, Cochrane Collaboration (2020) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley-Blackwell, Hoboken

Cited by

See all 21

Metadata

Authors
Fredman, D., McNeil, R., Eldar, O., Leader, A., Gafter-Gvili, A., & Avni, T.
Affiliations
Tel Aviv University (IL)
Corresponding author
Fredman, Danielle
Venue
Journal of Thrombosis and Thrombolysis
Published
2023-12-21
Volume
57
Issue
3
Pages
453-465
ISSN
  • 0929-5305 (ISSN-L)
  • 1573-742X
OpenAlex
W4390049377
Cited by
21
References
32
Citations by year
2026: 11 · 2025: 6 · 2024: 4
FWCI
1.47
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Thrombosis and Thrombolysis (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
rivaroxaban, apixaban, venous thromboembolism, direct oral anticoagulants, recurrent venous thromboembolism, major bleeding, clinically relevant non-major bleeding, anticoagulant safety, anticoagulant efficacy
MeSH terms
Rivaroxaban, Hemorrhage, Humans, Pyrazoles, Pyridones, Treatment Outcome, Venous Thromboembolism, Observational Studies as Topic, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies. https://app.cochat.ai/papers/10.1007/s11239-023-02926-3
The paper
Fredman, D., McNeil, R., Eldar, O., Leader, A., Gafter-Gvili, A., & Avni, T. (2023). Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-023-02926-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.